At a research facility just outside of Houston, scientists have found a plant that has COVID-19 treatment potential. Photo courtesy of iBio

The original version of this story included some factual inaccuracies due to misinformation from a source. The story below has been corrected.

In a 130,000 square-foot facility outside of Bryan-College Station, iBio is growing the makings of new types of therapeutics for fibrosis, cancer, and even COVID-19.

The company, which moved its headquarters from New York to Texas in July, uses novel biopharma methods to produce the vital molecules and antigens used for vaccines and other types of medical treatments through plants in a fast, sustainable way.

Other methods of creating biopharmaceutical require scientists to engineer cells to create a desired protein, which can be one of the most time consuming parts of the process, IBio's CEO Tom Isett explains. However, through iBio's FastPharming method, the team let's the plants do most of the work.

IBio introduces an Agrobacterium carrying a desired gene to manipulate the plant's DNA.

"[The bacteria] takes over the machinery of the plant leaves and it then produces the protein of interest or the biopharmaceutical that we were going to want to make for people," Isett says.

IBio then harvests the leaves and purifies the proteins to make the biopharmaceutical of interest. The entire process can save anywhere from six to 18 months in development, he estimates.

Too, if there's demand for more of the product, through this process, all scientists need to do is grow more plants.

"We have a linear scale up, it's very straightforward," says Peter Kipp, iBio's VP of translational science and alliance management. "And using some of the other competing methodologies, as you go to a bigger scale, you have new technical problems that you have to solve, but we don't."

The team discovered that an Australian species of the tobacco plant could be one of their biggest conduits in their process.

"It just grows like a weed. And that's why we like it," Kipp says.

The plant expends most of its energy in creating its leaves, where IBio extracts most of its proteins from. The plants are grown in the company's indoor, vertical hydroponic facility and are able to be harvested about every six weeks, and (it's important to note) does not contain nicotine.

IBio used their FastPharming process to introduce two vaccine candidates and a therapeutic in about six week's time. However, Isett says they're not just a COVID-19 vaccine company.

"We're mostly focused in other areas. But when [COVID] showed up, we did want to go in and see if we could address it using the speed of our system," he says.

Solugen, which uses plant-centered biotechnology to produce environmentally friendly chemicals, has raised an additional $30 million and is speculated to soon reach unicorn status. Photo via solugentech.com

Houston startup raises $30M, plans to be 'next iconic chemical company' with plant-based alternatives

climate tech

While Forbes recently anointed Houston-based Solugen Inc. as one of the next billion-dollar "unicorns" in the startup world, Dr. Gaurab Chakrabarti shrugs off the unicorn buzz.

Chakrabarti, a physician and scientist who's co-founder and CEO of the startup, concedes he doesn't know whether Solugen will be worth $1 billion or not. But he does know that the startup aspires to be a key competitor in the emerging "climate tech" sector, whose players strive to combat climate change. Chakrabarti estimates the climate-tech chemical space alone represents a global market opportunity valued at $1 trillion to $2 trillion per year.

Solugen's overarching goal in the climate-tech market: Replace petroleum-based chemicals with plant-based substitutes.

"I'd love it if we were the poster child that drives climate tech to be the next big, sexy trend," Chakrabarti says.

Chakrabarti acknowledges Solugen's investors, executives, and employees hope the startup succeeds financially. But success, he believes, goes beyond making money and plotting an exit strategy. Instead, Chakrabarti emphasizes "a shift in thinking" on climate tech that he says promises to transform the fledgling sector into a "true niche" that'll be "good for everyone."

"Who cares if people are all hyped up for the wrong reasons?" says Chakrabarti, referring to the unicorn speculation.

Solugen sits at the crossroads of biology and chemistry. In short, the startup taps into plant-centered biotechnology to produce environmentally friendly chemicals and "decarbonize" the chemical industry.

"Quite simply, we want to become the next DowDuPont or the next iconic chemical company, but using principles of green chemistry instead of principles from petroleum chemistry," Chakrabarti says.

If Solugen does reach the icon stratosphere, Chakrabarti envisions it doing so on a speedy schedule. In the traditional petrochemical market, it can take 10 to 20 years to put a new product on the market, he says. "I don't have that kind of time. I'm a very impatient person," Chakrabarti says.

Gaurab Chakrabarti Gaurab Chakrabarti, CEO and co-founder of Solugen, isn't paying any mind to his company's predicted unicorn status — rather he's focusing on the difference he can make on reducing carbon emissions. Photo via solugentech.com

Spurred by that restlessness, Chakrabarti seeks to propel Solugen's products from concept to commercialization in the span of two years. He says the startup already has proven the ability to do that with its sugar-derived hydrogen peroxide product.

"We're going to continue to do that, and it would be great if we can continue demonstrating new [products] coming to market once a year," says Chakrabarti, who grew up in Sugar Land.

Solugen seems to have plenty of financial fuel to make that happen. In April, Solugen raised $30 million in venture capital as an add-on to its Series B funding, which initially closed May 2019. That brings its total VC haul to $68 million since it was founded in 2016, according to Forbes. The recent funding lifted the company's valuation to $250 million, putting it $750 million away from unicorn territory.

Chakrabarti doesn't dismiss the notion of an eventual IPO for Solugen but says being acquired isn't "terribly interesting to me."

"If you want to make money, you can always go be a banker," he notes.

Chakrabarti estimates Solugen will generate $30 million to $40 million in revenue this year, up from $12 million in 2019. Profit remains elusive, though, as the company pours its gains into R&D. The company graduated in 2017 from the Y Combinator startup accelerator. Aside from Y Combinator and Unicorn Venture Partners, investors include Founders Fund, Refactor Capital, Fifty Years, and KdT Ventures.

Solugen's current lineup features fewer than a half-dozen products, which are sold to industrial and government customers. Hundreds more products are in the pipeline for use in sectors like agriculture and energy, Chakrabarti says.

"It's one of the blessings and curses of this company — there's always something to work on, always something big to scale up," says Chakrabarti, who earned his M.D. and Ph.D. from the University of Texas Southwestern Medical Center in Dallas.

Working on selling Solugen's current products and developing its new products are 70 employees, located at its headquarters in Houston and its new production facility in Lubbock. By the end of this year, the startup should employ close to 100 people, Chakrabarti says.

Chakrabarti hesitates to identify Solugen's competitors, as he believes a perceived rival very well could end up becoming a partner.

"I think everyone eventually should be a partner of Solugen, not competition," he says. "It's an ideology that's actually the competition, an ideology like, 'We've always used petrochemistry. This is just how it's been done.'"

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston firm invests $150M in leading 'lab on a chip' medical diagnostics co.

fresh funds

Houston-based health technology investment firm Hamershlag Private Capital Management Limited (HPCM) announced a $150.15 million venture investment in Patho Care LLC.

Patho Care is a “lab on a chip” medical diagnostics company known for its noninvasive point-of-care testing platforms, such as its Raman spectroscopy-based platform.

Its digital point-of-care testing devices are programmable, mobile, and reusable and can detect current or future respiratory bacterial or viral infections. The company says the technology is more cost-effective and provides results faster than traditional diagnostic methods.

“Patho Care LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” L. Mychal Jefferson, Chairman of Hamershlag, said in a news release.

The transaction was structured as an acquisition and recapitalization using newly issued common stock and cash, which will work through a newly formed entity, PathoCare Holdings Inc. The deal will also facilitate the repayment of Patho Care LLC's existing financial obligations and settle Patho Care’s outstanding notes, helping ensure the company’s financial readiness, according to the release.

The investment will help Patho Care LLC improve operational efficiencies, broaden its service offerings and continue to innovate in the diagnostic testing space. The companies hope the collaboration will help “unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology,” according to a news release.

“Our commitment to delivering transformative value through innovative investments underscores our confidence in Patho Care’s vision and capabilities,” Jefferson added.

10+ can't-miss Houston business and innovation events for February

WHERE TO BE

From talks with the hall-of-fame beauty business founders to agtech and AI summits, Houston will host a number of events focused on innovation and innovators in February.

Here’s what not to miss and how to register.

Note: This post might be updated to add more events.

Feb. 7 – SheSpace Offsite: Coffee & Connection

Get out of the office and head over to Midtown network with fellow SheSpace members and working women via coffee and conversation.

This event is Friday, Feb. 7, from 2-4 p.m. at Kefita Coffee. RSVP here.

Feb. 11 – Texas Business Hall of Fame x Ion: Creators Series with Founders Janet Gurwitch (Laura Mercier) and Tiffany Masterson (Drunk Elephant)

Take part in Texas Business Hall of Fame’s launch of its Creators 2025 speaker series. Janet Gurwitch, founder of Laura Mercier, and Tiffany Masterson, founder of Drunk Elephant, will discuss lessons learned while building their global retail brands and their successful exits.

This event is Tuesday, Feb. 11, from 8–10 a.m. at the Ion. Register here.

Feb. 11 – How to Start a Startup

Gain insight from Mercury Fund’s Heath Butler and stick around for a happy hour afterward. This session, originally scheduled for Jan. 21, is geared toward entrepreneurs, small business owners, investors and academic partners

This event is Tuesday, Feb. 11, from 5:30–7 p.m. at the Ion. Register here.

Feb. 15 – Ion Family Tech Day: Youth Entrepreneurship with Lemonade Day University

Bring the whole family out to the Ion for a family-friendly entrepreneurial workshop with Lemonade Day. Kids can compete in a pitch competition to win free supplies, and trained instructors will coach kids on how to set goals, develop a business or marketing plan and budget, create a brand, save and invest money, and more.

This event is Saturday, Feb. 15, from 10 a.m.–12:30 p.m. at the Ion. Register here.

Feb. 18 — Female Founders and Friends

Connect with like-minded female founders, funders, and allies at this recurring event. Female Founders & Friends is open to all industries and coffee is provided.

This event is Tuesday, Feb. 18, at 9 a.m. at Sesh Coworking. Register here.

Feb. 20 — Diaspora Africa Conference

Come together to hear inspiring speakers, participate in interactive workshops and network with others who are passionate about African heritage and the contributions of the African diaspora. This event will showcase African innovation and allow attendees to connect with funding sources actively seeking high-growth opportunities in Africa.

This event is Thursday, Feb. 20, from 9 a.m.–6 p.m. at the Ion. Register here.

Feb 20–21 — TMC AI Summit 2025

The TMC AI Summit aims to translate advanced AI innovations into practical solutions for real-world biomedical and health care challenges by bringing together researchers, clinicians, and industry leaders. The event features various workshops and tracks with keynote speakers from Rice University, UTHealth, Microsoft Health Futures and other organizations.

This event is Thursday, Feb. 20, from noon–7 p.m. and Friday, Feb. 21, from 8 a.m.–5 p.m. at TMC Helix Park in the TMC3 Collaborative Building. Register here.

Feb. 25 — Houston Methodist Leadership Speaker Series at Ion - Tesha Montgomery

Hear from Houston Methodist’s SVP of System Patient Access about how the health care system is approaching improvements to patient access and highlighting women in health care leadership. Audiences can participate in a 30-minute discussion following Montgomery’s remarks.

This event is Tuesday, Feb. 25, from 4:45–6 p.m. at the Houston Methodist Tech Hub at the Ion. Register here.

Feb. 26 — Inaugural HTX AgTech Rodeo Innovation Summit 2025

Network with farmers, founders, startups and investors at the first-ever HTX AgTech Rodeo Innovation Summit. The all-day event will feature panels, fireside chats, a Saddle Up Pitch Competition and reception with live music.

This event is Wednesday, Feb. 26, from 8:30 a.m.–8 p.m. Find more information and register here.

Feb. 27 — NASA Tech Talks

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.


This event is Thursday, Feb. 27, from 6-7 p.m. at the Ion. Register here.

Feb. 27–28 – QVIDTVM x The Ion: Inaugural Hack Day Competition

Investment firm QVIDTVM and the Ion are calling all data scientists, analysts, developers and innovators to a new hack day. Participants will aim to find the total value of real estate platformed by Airbnb globally and can participate in a Fireside Chat on AI with Nick King, founder and CEO of Data Kinetic. Teams can include up to four people and prizes for first through third place will be awarded.

This event is Thursday, Feb. 27, at 9:30 a.m. until Friday, Feb. 28, at 5 p.m. at the Ion. Register here.


Houston humanoid robotics startup secures millions in pre-seed funding

my robot

A Houston-based startup developing AI-powered humanoid robots for manufacturers and other businesses has raised more than $10 million in pre-seed funding less than a year after its founding.

Nic Radford, co-founder and CEO of Persona AI, declines to disclose the amount raised. However, he tells InnovationMap that it was an eight-figure total.

While not providing names, Radford says Persona AI’s first outside investors include VC firms, institutions and high-net-worth individuals in the U.S., London and Singapore. One of the high-net-worth investors was among the first employees at SpaceX, Elon Musk’s Brownsville, Texas-based aerospace company, according to Rodford.

No Houston investors have participated in the funding round yet. However, Radford says he’s working on bringing aboard one local investor before the round closes.

“Houston’s the perfect city to do a company like this in,” Radford says. “It’s just not the perfect investor climate, but it's the perfect city from a customer aspect.”

Persona AI’s pre-seed funding comes amid a dramatic surge in investment capital chasing AI startups. Global funding for AI-related companies exceeded $100 billion in 2024, up more than 80 percent from the 2023 total, Crunchbase data shows.

Radford and co-founder Jerry Pratt, the startup’s chief technology officer, bootstrapped Persona AI. The third co-founder, Jide Akinyode, serves as Persona AI’s chief operating officer. Radford and Akinyode helped develop NASA’s six-foot-two-inch Valkyrie humanoid robot and both are former employees of Webster-based Nauticus Robotics, a provider of autonomous subsea robots.

Persona AI launched last June in what Radford calls “anti-stealth mode.” The startup is close to announcing its first customer, which does business in the industrial sector. Persona AI expects customers to take delivery of its first robot in 18 to 24 months, Radford says.

Persona AI will operate primarily as a robotics-as-a-service provider, with the company retaining ownership of the lifelike robots and selling the labor that they supply. Radford says the startup’s robots will help alleviate a shortage of skilled labor in sectors like manufacturing.

A report released last year by consulting firm Deloitte and the Manufacturing Institute declared that as many as 1.9 million manufacturing jobs in the U.S. could go unfilled between 2024 and 2033 due to a skills gap and a tight labor market.

Persona AI competes in a market with enormous potential. In November, analysts at Citi Global Insights projected that the global market for humanoid robots could soar to $7 trillion by 2050, with 650 million of the robots tackling all sorts of jobs.

Radford says Personal AI is developing a “rugged” five-foot-eight-inch humanoid robot that’s able to survive tough indoor and outdoor conditions and take on tasks like carting around sheet metal, tending to metal-stamping machines, moving storage bins and handling order fulfillment. He likens his company’s robot prototype to a Ford F-150 pickup truck, compared to the less-sturdy versions produced by robotics competitors, which he calls the Toyota Camry or Volkswagen Beetles of the field.

Radford says he and his team “are building a really compelling startup in one of the hottest markets and one of the greatest cities.” Employees work at Persona AI’s headquarters in Houston or its satellite office in Pensacola, Florida, where Pratt is located.

“We don’t hire anybody that’s not a rock star or superstar,” says Radford, “and I think the city is going to benefit tremendously from our efforts at Persona.”

Radford saw his last company, Nauticus Robotics, from founding to IPO, left the company in January and previously told InnovationMap that he couldn't get the idea of advancing humanoid robotics out of his head. Read more here.